Michael Rudenko

Prof. Michael Rudenko

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2019 in Allergy
Verified
Journal Article
Closed access
PDF file
PMPaolo Maria Matricardi
Paolo Maria Matricardi
SDStephanie Dramburg
Stephanie Dramburg
AAAlberto Alvarez‐Perea
Alberto Alvarez‐Perea
DADarío Antolín-Amérigo2
Darío Antolín-Amérigo2
CAChristian Apfelbacher
Christian Apfelbacher
IAIoana Agache
Ioana Agache

21 April 2020 in Allergy
Verified
Journal Article
Closed access
EJErika Jensen-Jarolim
Erika Jensen-Jarolim
Martin BachmannMartin Bachmann
Martin Bachmann
SBSergio Bonini
Sergio Bonini
LJLars Jacobsen
Lars Jacobsen
MJMarek Jutel
Marek Jutel
TKThomas Martin Kündig
Thomas Martin Kündig

4 December 2021 in Allergy
Verified
Journal Article
Open access
PDF file
Mojca Bizjak-SuranMojca Bizjak-Suran
Mojca Bizjak-Suran
MKMitja Košnik
Mitja Košnik
Dejan DinevskiDejan Dinevski
Dejan Dinevski
STSimon Francis Thomsen
Simon Francis Thomsen
DFDaria Fomina
Daria Fomina
MMMarcus Maurer
Marcus Maurer
Background: Cold urticaria (ColdU), that is, the occurrence of wheals or angioedema in response to cold exposure, is classified into typical and atypical forms. The diagnosis of typical ColdU relies on whealing in response to local cold stimulation testing (CST). It can also manifest with cold‐induced anaphylaxis (ColdA). We aimed to determine risk factors for ColdA in typical ColdU.Methods: An international, cross‐sectional study COLD‐CE was carried out at 32 urticaria centers of reference and excellence (UCAREs). Detailed history was taken and CST with an ice cube and/or TempTest® performed. ColdA was defined as an acute cold‐induced involvement of the skin and/or visible mucosal tissue and at least one of: cardiovascular manifestations, difficulty breathing, or gastrointestinal symptoms.Results: Of 551 ColdU patients, 75% (n = 412) had a positive CST and ColdA occurred in 37% (n = 151) of the latter. Cold‐induced generalized wheals, angioedema, acral swelling, oropharyngeal/laryngeal symptoms, and itch of earlobes were identified as signs/symptoms of severe disease. ColdA was most commonly provoked by complete cold water immersion and ColdA caused by cold air was more common in countries with a warmer climate. Ten percent (n = 40) of typical ColdU patients had a concomitant chronic spontaneous urticaria (CSU). They had a lower frequency of ColdA than those without CSU (4% vs. 39%, p = .003). We identified the following risk factors for cardiovascular manifestations: previous systemic reaction to a Hymenoptera sting, angioedema, oropharyngeal/laryngeal symptoms, and itchy earlobes.Conclusion: ColdA is common in typical ColdU. High‐risk patients require education about their condition and how to use an adrenaline autoinjector.

20 July 2023 in Viruses
Verified
Journal Article
Open access
PDF file
EKEmek Kocatürk
Emek Kocatürk
MRMelba Munoz Roldan
Melba Munoz Roldan
DEDaniel Elieh-Ali-Komi
Daniel Elieh-Ali-Komi
PCPaulo Criado
Paulo Criado
JPJonny Peter
Jonny Peter
MMMarcus Maurer
Marcus Maurer
Since more than a century ago, there has been awareness of the connection between viral infections and the onset and exacerbation of urticaria. Our knowledge about the role of viral infection and vaccination in acute and chronic urticaria improved as a result of the COVID-19 pandemic but it has also highlighted knowledge gaps. Viral infections, especially respiratory tract infections like COVID-19, can trigger the onset of acute urticaria (AU) and the exacerbation of chronic urticaria (CU). Less frequently, vaccination against viruses including SARS-CoV-2 can also lead to new onset urticaria as well as worsening of CU in minority. Here, with a particular focus on COVID-19, we review what is known about the role of viral infections and vaccinations as triggers and causes of acute and chronic urticaria. We also discuss possible mechanistic pathways and outline the unmet needs in our knowledge. Although the underlying mechanisms are not clearly understood, it is believed that viral signals, medications, and stress can activate skin mast cells (MCs). Further studies are needed to fully understand the relevance of viral infections and vaccinations in acute and chronic urticaria and to better clarify causal pathways.

17 April 2025 in Allergy
Verified
Journal Article
Closed access
LKLudger Klimek
Ludger Klimek
HBH. A. Brough
H. A. Brough
SAStefania Arasi
Stefania Arasi
STSanna Toppila-Salmi
Sanna Toppila-Salmi
CBC. Bergmann
C. Bergmann
MTMaría J Torres
María J Torres

9 April 2024 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Open access
ICIvan Chérrez-Ojeda
Ivan Chérrez-Ojeda
Jean BousquetJean Bousquet
Jean Bousquet
AGAna M. M Giménez-Arnau
Ana M. M Giménez-Arnau
KGKiran Godse
Kiran Godse
Dorota KrasowskaDorota Krasowska
Dorota Krasowska
MMMarcus Maurer
Marcus Maurer
Patient-reported outcome measures (PROMs) are validated and standardized tools that complement physician evaluations and guide treatment decisions. PROMs are crucial for monitoring atopic dermatitis (AD) and chronic urticaria (CU) in clinical practice, but there are unmet needs and knowledge gaps regarding their use in clinical practice. We investigated the global real-world use of AD and CU PROMs in allergology and dermatology clinics as well as their associated local and regional networks. Across 72 specialized allergy and dermatology centers and their local and regional networks, 2,534 physicians in 73 countries completed a 53-item questionnaire on the use of PROMs for AD and CU. Of 2,534 physicians, 1,308 were aware of PROMs. Of these, 14% and 15% used PROMs for AD and CU, respectively. Half of physicians who use PROMs do so only "rarely" or "sometimes". AD and CU PROM usage is associated with being female, younger, and a dermatologist. POSCORAD and UAS were the most utilized PROMs for AD and CU, respectively. Monitoring disease control and activity are the main drivers of the use of PROMs. Time constraints were the primary obstacle to using PROMs, followed by the impression that patients dislike PROMs. AD and CU PROM users would like training in selecting the proper PROM. Even though PROMs offer several benefits, their use in routine practice is suboptimal, and physicians perceive barriers to their use. It is essential to attain higher levels of PROM implementation in accordance with national and international standards.